A B S T R A C T A monoclonal antibody to a neoantigen of the C9 portion of the membrane attack complex (MAC) of human complement has been developed and characterized. The distribution of this neoantigen was assessed by indirect immunofluorescence microscopy in nephritic and nonnephritic renal diseases. The antibody (Poly C9-MA) reacted on enzyme-linked immunosorbent assay (ELISA) with a determinant in complement-activated serum that was undetectable in normal human serum (NHS). Zymosan particles incubated in NHS had positive immunofluorescent staining with Poly C9-MA; however, binding of Poly C9-MA was not observed with zymosan particles incubated in sera deficient in individual complement components C3, C5, C6, C7, C8, or C9. Reconstitution of C9-deficient sera with purified C9 restored the fluorescence with Poly C9-MA. Poly C9-MA reacted positively by ELISA in a dose-dependent manner with purified MC5b-9 solubilized from membranes of antibody-coated sheep erythrocytes treated with NHS but not with intermediate complement complexes. Poly C9-MA also reacted in a dose-dependent manner on ELISA and in a radioimmunoassay with polymerized C9 (37°C, 64 h) (poly C9) but not with monomeric C9. Increasing amounts of either unlabeled poly C9 or purified MC5b-9 inhibited the '251-poly C9 RIA in an identical manner. These studies demonstrate that Poly C9-MA recognizes a neoantigen of C9 common to both the MAC and to poly C9. By immunofluorescence, Poly C9-MA reacted minimally with normal Dr. Falk is supported by U. S. Public Health Service training grant AM 07087.
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INTRODUCTION
The complement system has been implicated in the pathogenesis of experimental and human renal disease by virtue of changes in serum levels and by the demonstration of complement components in diseased tissue (1) . One of the mechanisms of complement-induced membrane damage is mediated through the assembly of terminal complement components into the membrane attack complex (MAC)' MC5b-9 (2). The 'Abbreviations used in this paper: DOC, sodium-desoxycholate; EA, antibody-coated sheep erythrocytes; EAC, complement-coated EA; ELISA, enzyme-linked immunosorbent assay; GBM, glomerular basement membrane; LPS, endotoxin lipopolysaccharide; MAC, membrane attack complex; MPGN, membranoproliferative glomerulonephritis; NHS, normal human serum; poly C9, polymerized C9; Poly C9-MA, monoclonal antibody to a neoantigen of C9; SLE, systematic lupus erythematosus; VBS, veronal-buffered saline.
five MAC precursor proteins assemble after cleavage of complement component C5 by classic or alternative complement pathway activation (3) . Once formed, the MAC binds with high affinity to phospholipid binding sites on cell membranes (4) . Presumably, the MAC is capable of physically inserting itself into and then reorganizing membrane lipid bilayers (5, 6) . In the process of assembly of the MAC, the terminal complement components undergo conformational changes exposing neoantigenic structures in C5b6 and in C5b67, recognized by previously described polyclonal antibodies (7) . The C5b67 complex is membrane bound, allowing for subsequent C8 and C9 attachment (6) . Recently, Podack et al. (8) have demonstrated that polymerization of C9 induced by cell-bound C5b-8 or by prolonged incubation of monomeric C9 at 37°C forms tubular structures with an ultrastructural appearance that resembles that of the isolated MAC. Additionally they have produced a polyclonal antiserum to a neoantigen(s) on polymerized C9 (poly C9) that is similar to the antigen(s) present on isolated MAC (9) .
Although the MAC has been recognized for several years on lymphocytes (10), polymorphonuclear leukocytes (11) , and platelets (12) , its presence in diseased tissues has been appreciated only recently. Biesecker et al. (13, 14) demonstrated that a polyclonal antibody to MAC fixes to immune deposits in the kidney and skin of patients with systemic lupus erythematosus (SLE).
In the course of studies of monoclonal antibodies to human renal basement membranes, we found and characterized a monoclonal antibody (Poly C9-MA) to a neoantigen present in the C9 portion of the MAC. In normal kidney tissue, this antigen is present in small vessels and minimally within the glomerular stalk, whereas in kidney tissue from a variety of diseases there is extensive deposition of this neoantigen of the MAC.
METHODS
Buffers. The following buffers were used: Veronal-buffered saline (VBS); VBS containing 0.15 mM CaC12 and 0.5 mM MgCl2 (VBS++); phosphate-buffered saline (PBS) (0.15 M NaCl, 0.01 M NaH2PO4, pH 7.4); 0.5 PBS (0.5 M NaCl, 0.01 M NaH2PO4, pH 7.4); PBS-EDTA (PBS with 10 mM EDTA); BEP buffer (5 mM Na borate with 10 mM EDTA, 1 mM phenylmethyl sulfonyl fluoride, pH 8.8) (15) ; enzymelinked immunosorbent assay (ELISA) coating buffer (0.1 M Na2CO3, pH 9.6); ELISA wash buffer (0.5 PBS with 0.05% Tween 20, Sigma Chemical Co., St. Louis, MO); citrate phosphate buffer (0.5 M citric acid and 0.1 M NaH2PO4, pH 5.0); and Tris-hydroxymethyl aminomethane-buffered saline (Trisbuffered saline; 0.10 M Tris, 0.15 M NaCl, pH 7.4).
Complement components and reagents. The following human complement proteins were purified as described previously: C5 (16), C6 (17) , C5b6 (18) , C7 (17) , C8 (19) , and C9 (20) . C5b67 complexes were formed by reacting 100 ug of C5b6 with 50 ug of C7 for 30 min at 37°C. Poly C9 was prepared by incubating purified C9 at 1 mg/ml for 64 h at 37°C in Tris-buffered saline containing 25 ,g soybean trypsin inhibitor (8) . Electron microscopic analysis of the poly C9 using a negative staining technique showed tubular structures identical to those previously reported (8) . Analysis of the purified poly C9 by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis was conducted on a 2.5-10% polyacrylamide gradient as previously described (9) . The purity of the preparation is demonstrated in Fig. 1 . By densitometric scanning in different preparations, 22-50% of the material was present in the poly C9 form. Some experiments were performed with functionally pure C8 and C9 (Cordis Laboratories, Inc., Miami, FL).
Zymosan (Becton-Dickinson and Co., Orangeburg, NY), cobra venom factor (Naja Naja) (Cordis Laboratories), and endotoxin lipopolysaccharide (LPS) from Escherichia coli 026:B6 (lot 613126, Difco Laboratories, Detroit, MI) were used as complement activators. Human sera deficient in specific complement components, Clr, C2, C3, C5, C6, C7, C8 (a,-y chain), C8 (,B chain), and C9 were characterized by component analysis as previously described (21) . An additional C9 deficient serum was a kind gift from Dr. Shinya Inai, Osaka, Japan. Single donor normal human cryoprecipitate (22) was obtained from the University of Minnesota Blood Bank.
Collagen types I, III, IV, and V were isolated from human placenta (23) , but without reduction, carboxymethylation, or repeated pepsin digestion. Laminin was a gift of Dr. Hynda Kleinman (National Institute of Dental Research), and fibronectin was a gift of Dr. Leo Furcht (University of Minnesota).
Development of the monoclonal antibody Poly C9-MA. Collagenase-digested normal human glomerular basement membrane (GBM) was prepared from kidney tissue that was obtained at the time of autopsy after accidental death (24, 25) . Balb/c female mice were immunized by an intraperitoneal injection of 100 ,g of GBM homogenized in complete Freund's adjuvant (Gibco Laboratories, Grand Island, NY), followed by two immunizations in PBS at intervals of 14 (27) . Supernatants from visible hybrid colonies were screened for antibody by indirect immunofluorescence on normal human kidney. Colonies of interest were subcloned by limiting dilution, then grown to culture volume, and injected into pristane-primed Balb/c female mice. Ascites fluid was harvested 7 to 14 d after injection (28) MC5b-9 complex isolation. MC5b-9 complexes were isolated from sheep erythrocytes as described by Ware et al. (15) . Briefly, antibody-sensitized sheep erythrocytes (EA) were incubated with human serum diluted in VBS++ for 60 min at 37°C. The complement-coated EA membranes (EAC) were washed three times in BEP buffer, centrifuged at 27,000 g and 4°C for 20 min, solubilized with Triton X-100 (Sigma Chemical Co.) or Zwittergent ionic detergent [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] (SB12, Calbiochem-Behring, La Jolla, CA) for 30 min at room temperature. The detergent-to-protein weight ratio was 40:1. The mixture was centrifuged at 27,000 g for 20 min and the supernatant was concentrated on a YM-30 membrane (Amicon Co., Lexington, MA), and stored at 4°C. Purified MC5b-9 was obtained from EAC membranes solubilized in SB12 and isolated by Bio-Rad A 15 M chromatography (Bio-Rad Laboratories, Richmond, CA) as previously reported (15) . Additional purified MC5b-9 was kindly provided by Dr. William Kolb (San Antonio, TX).
Reconstitution experiments were performed with EACI-7 cells prepared as follows: 1.0 ml of C8-deficient serum was incubated with 1.6 X 109 EA for 60 min at 37°C and then washed six times with cold VBS++ to remove residual serum components. The absence of C9 on the EAC1-7 intermediates was demonstrated by the lack of aggregation of these cells by anti-human C9 antiserum. EAC1-7 intermediates were then incubated at 370C for 60 min with 2,000 hemolytic units of C8 alone or 2,000 hemolytic units of both C8 and C9, or 2,000 hemolytic units of C9 alone. The EAC membranes were washed, solubilized, and concentrated by ultrafiltration as described above. Unlysed EA cells (those incubated with heat-inactivated serum or C8-deficient serum) were lysed during the BEP buffer washes. A similar experiment was performed in which solubilized EAC membranes were obtained from EA incubated in C9-deficient serum alone, or C9-deficient serum reconstituted with 2,000 hemolytic units of C9.
Serum C5b-9 (SC5b-9) was made by incubating NHS with LPS (300 Mg/ml of serum) or cobra venom factor (20 U/ml of serum) for 1 h at 37°C. These sera were placed directly on microtiter plates for ELISA. Binding to the plates was similar whether antigens were incubated in coating buffer or in PBS.
Analysis of reactivity of Poly C9-MA with poly C9 and with monomeric C9. The interaction of Poly C9-MA with poly C9 and with monomeric C9 was investigated by ELISA and by a radioimmunoassay (RIA) . For the RIA, C9 was labeled with 1251 by a lactoperoxidase procedure (34) Inhibition of the '25I-poly C9 RIA by poly C9 and purified MC5b-9. Inhibition of '251-poly C9 binding to the immunobeads was accomplished using unlabeled cold poly C9 or purified Immunobeads were incubated with Poly C9-MA supernatant, washed as above, and transferred in PBS-1% DOC to BSA-coated polypropylene tubes. Unlabeled poly C9 (protein concentration of 100 pg/ml) that had been stored in PBS-1% DOC was then added to the immunobeads in 10-pul increments. After 1 h of incubation on a rotating platform at room temperature, a constant amount of 125I_ poly C9 was added and total radioactivity measured. After 10 min of incubation at room temperature, the beads were washed and the bound counts determined. In other experiments, 10-Al increments of purified MC5b-9 (protein concentration of 100 pg/ml) were added under exactly the same conditions instead of unlabeled poly C9.
Patients. Kidney tissue was selected from two groups of patients. One group included 16 patients with glomerulonephritis: membranoproliferative glomerulonephritis (MPGN) type I (n = 3), MPGN type II (n = 2), membranous nephropathy (n = 3), SLE, n = 3), IgA nephropathy (n = 3), and anaphylactoid purpura nephritis (n = 2). Tissue was obtained by percutaneous renal biopsy from 14 of these patients with serum creatinine levels ranging from 0.7 to 2.3 mg/dl. In two other patients, both with MPGN type II, the kidney tissue was obtained at the time of nephrectomy, before renal transplantation. The second group of patients included 17 patients with diseases other than glomerulonephritis: diabetes mellitus (n = 7), hypertension (n = 3), obstructive uropathy (n = 3), congenital dysplasia (n = 2), and amyloidosis (n = 2). Kidney tissue was obtained by percutaneous renal biopsy in eight patients (four with diabetes mellitus, and one each with hypertension, obstructive uropathy, congenital dysplasia, and amyloidosis); the serum creatinine of these patients ranged between 0.6 and 2.1 mg/dl. Kidney tissue from the other nine patients in the nonnephritic group was obtained at the time of nephrectomy, before renal transplantation. All tissues were evaluated and characterized by light and electron microscopy as previously described (35) (36) (37) . Routine immunofluorescent studies were carried out with polyclonal antisera to human IgG, IgM, IgA, Clq, C3, C4, properdin, albumin, and fibrinogen (36, 38) . The immunohistochemical localization of immunoglobulins and other antigens will not be reported in this paper. There was a good correlation between the deposition of immunoglobulin and C3 in kidney tissue from patients with glomerulonephritis, except for those with MPGN. In the latter disease, the deposition of C3 was more extensive than that of immunoglobulin (37) . In tissue from patients with nonnephritic disease, a similar discrepancy was obtained between the deposition of C3 and that of immunoglobulin, as previously reported (36, 38) .
RESULTS
Initial studies with Poly C9-MA. The monoclonal antibody (Poly C9-MA) [IgG1, K] was developed after immunization with collagenase-digested normal human basement membranes. However, Poly C9-MA did not react on ELISA with either the collagenase-digested GBM material used for immunization or the known constituents of renal extracellular matrices: collagen type I, III, IV, V, fibronectin, and laminin. Each antigen was tested with an appropriate positive control antiserum. Immunohistochemical studies on human kidney specimens from patients with glomerulonephritis suggested a fluorescence pattern of Poly C9-MA similar to that observed for anti-C3 antisera. However, extensive absorption of Poly C9-MA with normal human plasma failed to diminish immunofluorescence. By ELISA, the optical density of the reaction of Poly C9-MA with 10 different samples of untreated normal human serum was 0.053±0.02 (mean±SD) (Fig. 2) . When each of these serum samples was activated with LPS, an OD of 0.193±0.11 was seen (P < 0.005). This difference was significantly inhibited by heat inactivation of the serum before addition of LPS (0.076±0.05, P < 0.01). A similar positive interaction was seen when serum was activated with cobra venom factor; no binding was observed with cryoprecipitate as well as with serum treated with 0.02 M EDTA before LPS activation. (Table I1 ). There was positive reactivity of polyclonal anti-human C9 with both poly C9 and MC5b-9 complexes, whereas the unrelated IgGI monoclonal antibody MBM10 had no reactivity (Table II) . When Poly C9-MA was reacted with 10-fold serial dilutions of MC5b-9 or poly C9 (initial protein concentrations of 100 /g/ml), there was a similar linear decrease in reactivity (Fig. 4) . The slopes of the MC5b-9 and poly C9 dose-dependent relationships as determined by linear regression analysis were -0.12 and -0.11, respectively. There was no binding of Poly C9-MA to purified C5, C8, C9, and to the intermediates C5b6 and C5b67 (Table II) . Because of the nature of our ELISA, inhibition studies could only be carried out with low concentrations of Poly C9-MA. Therefore a 1:400 dilution of Poly C9-MA supernatant yielding an OD of 0.10 was selected. 1 ug of purified MC5b-9 was incubated with Poly C9-MA for 1 h at room temperature and overnight at 4°C. The mixture was then centrifuged at 27,750 g for 30 min. The OD of the absorbed Poly C9-MA was 0.03, which was identical to that of the control using the peroxidase-labeled antibody without the primary antibody.
To verify the requirement of C9 for recognition of Poly C9-MA, EAC1-7 and EAC1-8 intermediates were formed by incubating EA in complement-defi- C9, which is only 1.4% of the uptake of poly C9. When 125I-poly C9 was added in increasing amounts, a doseresponse curve was obtained (Fig. 5 A) . Increasing the amounts of '25I-C9 did not induce binding to Poly C9-MA.
When increasing amounts of either unlabeled poly C9 or purified MC5b-9 were added to a constant amount of '251-poly C9, identical dose-response inhibition curves were obtained (Fig. 5 B) . Although there was no inhibition of this RIA with 50 ,ul of NHS (bound/free ratio of 1.7), there was inhibition by the addition of 50 gl of human serum activated with LPS (a bound/free ratio of 0.40). ;Lg/ml. The slope of the Poly C9 relationship was -0.11, while that of MC5b-9 was -0.12 (r = 0.95 for both reactions). cient sera. Because of limited amounts of complementdeficient sera, purification of these complexes by gel filtration chromatography was not feasible. Membranes solubilized by Triton X-100 from EA cells incubated in NHS reacted with Poly C9-MA in a manner similar to that of purified MC5b-9 (Table II) . As a control, solubilized membranes that had been incubated in heat-inactivated serum did not bind to Poly C9-MA. EAC membranes bearing C1-7 were produced by incubating EA in C8 deficient serum. EACl-8 was formed by the addition of functionally purified C8 to the extensively washed EAC1-7, resulting in hemolysis. A control was performed by adding C9 alone to the EAC1-7 cells without the addition of C8. EAC membranes were then solubilized with Triton X-100 and reacted on ELISA with Poly C9-MA and the control monoclonal antibody MBM1O. As shown in Table II Amount of Poly C9 (X) or MC5b-9 (0) (ipl) Immunofluorescence studies. Poly C9-MA binding was initially recognized on the internal elastic lamina and media of vessels and focally in the juxtaglomerular zone and mesangial stalk region of normal adult kidney sections (Fig. 6 ). There was no detectable immunofluorescence with normal fetal kidney; with other regions of mature human kidney, muscle, or skin; or with isolated lymphocytes, monocytes, polymorphonuclear leukocytes, or platelets. However, immunofluorescent positive vessels were observed in normal human liver and spleen. By phase-epifluorescence microscopy, Poly C9-MA was often recognized on phase-dense material or particles in extracellular membranes. These densities did not stain with hematoxylin-eosin, Masson Trichrome, periodic acid-Schiff, Von Kossa, Prussian blue, sudan black D, or colloidal iron stains.
The distribution and intensity of Poly C9-MA and of polyclonal antisera to human C3, C5, C6, C7, C8, and C9 were assessed on kidney sections from a variety of renal diseases. In general, Poly C9-MA bound to sites that reacted with goat antisera to the individual human complement components C5, C6, C7, C8, and C9. However, the intensity of staining was different. There was uniform conjunction of Poly C9-MA and anti-C5, which stained all tissue strongly. Antisera to C6 and C7 reacted with trace intensity, whereas anti-C8 and anti-C9 were recognized with moderate intensity. When visible, these antisera localized in the same areas as Poly C9-MA staining.
When the distribution of the MAC (as interpreted by reactivity with Poly C9-MA) was compared with that of C3, the pattern found in tissue from patients with glomerulonephritis was different from that in tissue from patients with nonnephritic diseases. In MPGN (type I and II), IgA nephropathy and anaphylactoid purpura, SLE, and membranous nephropathy, there were areas of homology in the distribution of C3 and the MAC (Fig. 7) . In MPGN type II, Poly C9-MA and anti-C3 encircled dense deposits in the glomerular and tubular basement membranes, and both antisera demonstrated mesangial rings typical of dense deposit material (37) . In IgA nephropathy and anaphylactoid purpura, the mesangial regions contained both the MAC and C3, although the latter was also trapped along the internal aspect of the GBM. In SLE, there was a close correlation between the distribution of C3 and the MAC in the glomerular mesangium and in subendothelial GBM deposits. In membranous nephropathy, C3 and the MAC were present in epimembranous deposits (Fig. 8) . However, in addition to areas of homology in these diseases, the MAC was frequently present in a coarse granular pattern (in phase dense areas) along tubular basement membranes in loci where C3 was consistently absent.
In diabetes, hypertension, obstructive uropathy, amyloid nephropathy, and congenital dysplasia, the MAC was present in greater abundance and frequently in different loci than C3. The MAC appeared in a coarse granular pattern along tubular basement membranes and Bowman's capsule in close conjunction with the phase-dense granules previously mentioned (Fig.  9) . The MAC deposition in vessel walls, internal elastic lamina, juxtaglomerular and mesangial regions and in areas of sclerosis was characteristically extensive (Fig.  10) . The MAC was generally not observed trapped along the internal aspect of the GBM, except in a focal granular pattern (Fig. 11) . In contrast, C3 was present focally in a linear pattern along basement membranes of the glomeruli, tubules, and Bowman's capsule; in a granular pattern in peripheral and stalk regions of the mesangium; and also in arteriolar media and intima, and frequently in the lumina of vessels. There When Poly C9-MA was absorbed with purified poly C9, there was complete abrogation of immunofluorescent staining on normal adult and diseased diabetic kidney tissue. Absorption with normal human plasma, diabetic plasma, and cryoprecipitate had no effect on Poly C9-MA immunofluorescence.
DISCUSSION
Complement-induced membrane damage is effected by the MAC, a multimolecular complex composed of the five terminal complement components. After cleavage of C5 into C5a and C5b, C6 and C7 attach to C5b, forming the C5b67 complex, which interacts with hydrophobic regions of lipid bilayers. The addition of C8 and C9 enhances the interaction of the complex with the membrane interior (5, 6, 39) . In the process of MAC assembly, the terminal components undergo conformational changes, creating binding sites for phospholipids that are released from and which cause the reorganization of membrane lipid complex (40, 41) or poly C9 (8) alone may form a bilayers (39) . The end result of MC5b-9 attachment transmembrane channel. is membrane damage, although the precise mechanism Prior studies have shown that the assembly of the whereby the MC5b-9 complex disrupts the membrane C5b-9 complex leads to the appearance of neoantigens barrier is uncertain. A transmembrane lipid channel associated with C5b6, C5b67 (7) , and poly C9 (9) . may be formed because of lipid bilayer reorganization This study has characterized a monoclonal antibody, (4, 6) , or, alternatively, the proteins of the MC5b-9 Poly C9-MA, which recognizes a neoantigen of the C9 FIGURE 11 Immunofluorescence of a normal human glomerulus demonstrating the contrast between (A) Poly C9-MA staining of an afferent arteriole and focally within the mesangium and (B) anti-C3 antisera staining of the same afferent arteriole and mesangium but also present along the inner aspect of the GBM. Polyclonal anti-C9 antisera stains this glomerulus in a pattern identical to that of Poly C9-MA.
Poly C9-MA. There is compelling evidence that the antigenic determinant recognized by Poly C9-MA is common to both MC5b-9 and poly C9: There was identical dose-response inhibition of the '25I-poly C9 RIA by unlabeled poly C9 and by purified MC5b-9, the slopes of the MC5b-9 and poly C9 dose-response relationship on ELISA were similar, there was inhibition on ELISA of poly C9 reactivity by MC5b-9 absorption of the antibody, and there was elimination of Poly C9-MA staining on normal and diseased human kidney by absorption with poly C9.
The development of a monoclonal antibody to the MAC from collagenase digested GBM may appear fortuitous. However, the GBM preparation is only partially purified and is known to consist of a variety of renal extracellular matrix and plasma antigenic determinants (42, 43) . That Poly C9-MA did not react with the preparation used for immunization reflects the scarcity of the antigen in this preparation, as well as the capacity to develop monoclonal antibodies to trace amounts of an antigen. Although the possibility that Poly C9-MA reacts with an epitope on an unrelated extracellular matrix protein is difficult to exclude, this likelihood is diminished by the lack of reaction on ELISA to known collagens or constituents of renal extracellular matrices (collagen types I, III, IV, V, fibronectin, and laminin), and the negative immunofluorescence of normal fetal kidney, human muscle and skin, and extracellular basement membranes of the adult human kidney.
Recently, Biesecker et al. (13) have demonstrated by immunofluorescence that a polyclonal antiserum to MAC binds to deposits in the kidney of patients with SLE nephritis. Although this antiserum recognizes a neoantigen(s), its specificity has not been characterized. A similar distribution of IgG, Clq, C4, and MAC was noted in glomeruli and blood vessels, whereas MAC was more frequently present in tubular deposits. Similar results were observed for the distribution of Poly C9-MA in various forms of glomerulonephritis. There was a close correlation in these diseases between the deposition C3 and that of the MAC in glomerular and mesangial regions. However, Poly C9-MA stained loci in tubular basement membranes that did not react with anti-C3, a finding which corroborates the observation of Biesecker et al. (13) in SLE.
In nonnephritic renal diseases, the MAC was present extensively in the mesangial and juxtaglomerular regions of glomeruli, internal elastic lamina and media of blood vessels, and tubular basement membranes. The deposition of the MAC was especially evident in tissues with sclerosis. In all of these loci, particularly in tubular basement membranes, there was little correlation between the distribution of C3 and that of the MAC. Additionally, the MAC was not present in loci such as the lumen of vessels and capillaries or along the internal aspect of the GBM where plasma proteins like C3 and albumin have been found. The presence of complement components in renal tissue from diseases such as hypertension, diabetes mellitus, obstruction, congenital dysplasia, and amyloid has been documented. In an immunohistochemical study of endstage kidney disease, it has been noted previously that immunoglobulins and classical and alternative pathway complement components were present in hyalinizing glomeruli, regardless of the cause of renal failure (36) . Verroust et al. (44) found that multiple complement components were detected by immunofluorescence in immunoglobulin-mediated glomerular injury. Even in instances where immunoglobulin was absent, alternative pathway complement components were present. The presence of the MAC in diseased tissue is more indicative of complement activation than demonstration of individual complement components, which may reflect nonspecific trapping, as previously suggested. The deposition of the MAC in small arterioles of normal adult kidney tissue and its absence in fetal specimens is difficult to explain, but may indicate low-grade complement activation in these sites.
Whether the membrane attack complex is damaging renal extracellular matrices in a manner analogous to cell membrane disruption is uncertain, but the extensive presence of the MAC in all diseased renal tissue, especially in areas of sclerosis, suggests that complement activation may play a role in sclerosis of endstage renal disease.
The frequent disparity in the distribution between the MAC and C3 in nonnephritic diseases was consistently observed. The reason for this difference is obscure, but may be explained in a number of ways. First, C3 may be present in a form not identified by polyclonal anti-C3 antiserum. Secondly, the initiation of attack complex activation may occur at a site distant from the MAC deposition, analogous to the observations of Gotze and Muller-Eberhard (45) who have shown that the C423 enzyme can affect the binding of C5, C6, and C7 to cell surfaces physically separated from where the C423 enzyme was bound. Thirdly, Polley and Nachman (46) have described C5b-9 activation by an interaction of platelet membranes, thrombin, and C3b that appears to be independent of the classical or alternative activation pathways. Although C3b is necessary for platelet-induced C5b-9 formation, its uptake on platelet membranes was less than that observed for C8. A similar phenomenon may occur on diseased renal basement membranes. Finally, C5b-9 formation or C9 polymerization may be induced by a mechanism not previously described and not requiring binding of C3. In this regard, it is of interest that a disparity also exists between the exten-sive deposition of the MAC and the limited localization of immunoglobulin, especially in tissue from patients with renal disease other than glomerulonephritis.
